GALDERMA GRP AG
201,00€
-12,00 (-5,63%)
19.11.2026, 22:59:15 Uhr
WKN: A407X6 ISIN: CH1335392721 Wertpapiertyp: Aktie Währung: Euro
- 1T
- 1W
- 1M
- 3M
- 6M
- 1J
- 3J
- 5J
- 10J
- Max
Zuletzt angesehen
- ROCKET PHARMAT... -0,36 -15,53% 1,98€
- IVISION TECH S.P.A. +0,06 +4,10% 1,40€
- EVOLUTION AB (PU)... +0,28 +0,36% 78,82€
- JACK HENRY + ASS. DL... +11,70 +8,16% 155,15€
- NANEXA AB +0,057 +7,06% 0,864€
- GPT GROUP UNITS +0,21 +7,47% 3,05€
Kursperformance
| Zeitraum | Kurs | % |
|---|---|---|
| 1 Tag | 213,00€ | -5,63% |
| 1 Woche | 216,61€ | -1,67% |
| 1 Monat | 195,89€ | +8,73% |
| 6 Monate | 178,42€ | +19,38% |
| Lfd. Jahr (YTD) | 182,26€ | +16,87% |
| 1 Jahr | 165,08€ | +29,03% |
| 3 Jahre | -- | -- |
| 5 Jahre | -- | -- |
Kursdaten
| Kurs | 201,00€ |
| Schluss Vortag | 213,00€ |
| Eröffnung | 201,00€ |
| Geld | 0,00€ |
| Brief | 0,00€ |
| Tages-Hoch | 201,00€ |
| Tages-Tief | 201,00€ |
| 52 Wochen-Hoch | 213,35€ |
| 52 Wochen-Tief | 149,40€ |
| Allzeit-Hoch | 213,35€ |
| Allzeit-Tief | 111,00€ |
Nachrichten
- BUSINESS WIRE: Mexico Becomes the First Market Worldwide to Receive Approval for Galderma’s Restylane® Shaype™ for Both Chin and Its First Jawline Indication - 13.11.2026, 07:00:03 Uhr
- BUSINESS WIRE: Galderma Announces Proposed Board Appointments and Chief Financial Officer Transition - 02.11.2026, 18:00:05 Uhr
- BUSINESS WIRE: Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines - 23.10.2026, 07:00:02 Uhr
- BUSINESS WIRE: Galderma Delivers Net Sales of 4.765 B USD in the First Nine Months, Up 25.1% at Constant Currency Year-on-Year, and Raises Full-Year Net Sales Guidance - 22.10.2026, 07:00:07 Uhr
- BUSINESS WIRE: AMWC Dubai 2026: Galderma Reinforces Its Injectable Aesthetics Leadership - 21.10.2026, 07:00:04 Uhr
- BUSINESS WIRE: PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis - 15.10.2026, 07:00:03 Uhr
- BUSINESS WIRE: Galderma Signs Agreement to Acquire ZO Skin Health, Strengthening Its Physician-Dispensed Skincare Offering - 14.10.2026, 07:00:05 Uhr
- BUSINESS WIRE: New Galderma Research Reveals More Than Half of Women Mistake Menopause-Related Skin Changes for Signs of Ageing - 13.10.2026, 07:00:06 Uhr
- BUSINESS WIRE: Fall Clinical 2026: Galderma Presents New Three-Year Nemluvio® Data Showing Deep and Lasting Skin Lesion and Itch Responses in Patients With Atopic Dermatitis Aged 12 and Older - 08.10.2026, 07:00:07 Uhr
- BUSINESS WIRE: 30 Years of Restylane®: Reshaping the Aesthetics Field Through Science-Led, Patient-Centric Innovation - 06.10.2026, 07:00:03 Uhr